Posted by Michael Wonder on 15 Apr 2021
FibroGen receives rare paediatric disease designation from the U.S. FDA for pamrevlumab for the treatment of Duchenne muscular dystrophy
15 April 2021 - FibroGen announced that the U.S. FDA has granted rare paediatric disease designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with Duchenne muscular dystrophy.
Pamrevlumab has also received Fast Track designation from the U.S. FDA and is currently being evaluated in two Phase 3 trials for the treatment of Duchenne muscular dystrophy.
